113 related articles for article (PubMed ID: 17102116)
1. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?
Kölby L; Bernhardt P; Johanson V; Wängberg B; Muth A; Jansson S; Forssell-Aronsson E; Nilsson O; Ahlman H
Ann N Y Acad Sci; 2006 Aug; 1073():491-7. PubMed ID: 17102116
[TBL] [Abstract][Full Text] [Related]
2. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
3. Aspects on radionuclide therapy in malignant pheochromocytomas.
Forssell-Aronsson E; Bernhardt P; Wängberg B; Kölby L; Nilsson O; Ahlman H
Ann N Y Acad Sci; 2006 Aug; 1073():498-504. PubMed ID: 17102117
[TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
5. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
6. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
[TBL] [Abstract][Full Text] [Related]
7. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
8. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
9. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.
Kölby L; Bernhardt P; Levin-Jakobsen AM; Johanson V; Wängberg B; Ahlman H; Forssell-Aronsson E; Nilsson O
Br J Cancer; 2003 Oct; 89(7):1383-8. PubMed ID: 14520475
[TBL] [Abstract][Full Text] [Related]
10. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
11. Histamine uptake by human endometrial cells expressing the organic cation transporter EMT and the vesicular monoamine transporter-2.
Noskova V; Bottalico B; Olsson H; Ehinger A; Pilka R; Casslén B; Hansson SR
Mol Hum Reprod; 2006 Aug; 12(8):483-9. PubMed ID: 16567367
[TBL] [Abstract][Full Text] [Related]
12. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
[TBL] [Abstract][Full Text] [Related]
13. Malignant pheochromocytoma in a population-based study: survival and clinical results.
Wängberg B; Muth A; Khorram-Manesh A; Jansson S; Nilsson O; Forssell-Aronsson E; Tisell L; Ahlman H
Ann N Y Acad Sci; 2006 Aug; 1073():512-6. PubMed ID: 17102119
[TBL] [Abstract][Full Text] [Related]
14. Localization of metastases from malignant pheochromocytoma in patients undergoing 131I-MIBG therapy with manually fused 123I-MIBG SPECT and CT images.
Kizu H; Takayama T; Tsushima H; Noguchi A; Nakajima K; Onoguchi M; Kinuya S
J Nucl Med Technol; 2008 Dec; 36(4):186-8. PubMed ID: 19008288
[TBL] [Abstract][Full Text] [Related]
15. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M
Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422
[TBL] [Abstract][Full Text] [Related]
16. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
Mairs RJ; Ross SC; McCluskey AG; Boyd M
J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
[TBL] [Abstract][Full Text] [Related]
17. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders.
Ferone D; Resmini E; Boschetti M; Arvigo M; Albanese V; Ceresola E; Pivonello R; Albertelli M; Bianchi F; Giusti M; Minuto F
J Endocrinol Invest; 2005; 28(11 Suppl International):111-7. PubMed ID: 16625859
[TBL] [Abstract][Full Text] [Related]
18. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro.
Oddstig J; Bernhardt P; Nilsson O; Ahlman H; Forssell-Aronsson E
Nucl Med Biol; 2006 Oct; 33(7):841-6. PubMed ID: 17045163
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic possibilities in metastatic pheochromocytoma].
Vierhapper H; Raber W
Zentralbl Chir; 1997; 122(6):494-7. PubMed ID: 9334119
[TBL] [Abstract][Full Text] [Related]
20. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.
Zhao Y; Zhong X; Ou X; Cai H; Wu X; Huang R
Front Med; 2017 Mar; 11(1):120-128. PubMed ID: 28213878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
